Recombinant Human Killer cell immunoglobulin-like receptor 2DL3 (KIR2DL3)

What is the molecular structure of KIR2DL3 and how does it differ from other KIR family members?

KIR2DL3 contains two immunoglobulin-like domains (D1 and D2) in its extracellular region, connected by a hinge region, and possesses a long cytoplasmic tail containing immunoreceptor tyrosine-based inhibitory motifs (ITIMs). The crystal structure of KIR2DL3 in complex with HLA-C*07:02 reveals that the D1 domain interacts with the HLA α1-helix via the A-B, C-C′ and E-F loops, while two recognition loops of the D2 domain (B-C and F-F′) and the D1-D2 interdomain loop make contacts with the HLA α2-helix .

KIR2DL3 adopts a hinge angle of approximately 77.1° between its D1 and D2 domains, which is similar to KIR2DL2's 77.7° but differs significantly in the relative positioning or "twist" of these domains. The D1 and D2 domains differ in twist by 13.3° and 10.4° respectively when comparing KIR2DL3 to KIR2DL2 . This structural difference affects how these receptors interact with their HLA-C ligands.

What are the key amino acid variations between KIR2DL3 and its closest relative KIR2DL2?

The extracellular domains of KIR2DL3001 and KIR2DL2001 differ at only four key positions:

The polymorphisms at positions 16 and 148 appear particularly significant as they are located proximal to the D1-D2 hinge and likely drive the relative positioning of these domains. Notably, Arg16 in KIR2DL2 reaches across the D1-D2 interface adjacent to the D2 C-C′ loop binding His146, while Pro16 in KIR2DL3 makes no direct interdomain interaction . Despite sharing approximately 94% sequence identity, these subtle differences result in distinct binding geometries when interacting with HLA-C molecules .

How does KIR2DL3 binding specificity compare to other inhibitory KIRs?

KIR2DL3 primarily recognizes HLA-C group 1 (C1) allotypes containing Asn80, but can also weakly bind to Lys80-containing C2 allotypes . Compared to its allelic variant KIR2DL2, KIR2DL3 exhibits lower avidity for HLA-C1 ligands. When compared to KIR2DL1 (which primarily recognizes HLA-C2), KIR2DL3 shows lower avidity but broader specificity for HLA-C1 ligands .

The distinct binding properties arise from structural differences that result in KIR2DL3's D1 domain sitting approximately 3Å more toward the C-terminus of the peptide-binding groove of HLA-C*07:02 relative to KIR2DL2 . This creates different contact patterns with the HLA molecule, where KIR2DL2 makes more extensive contacts to the HLA α1-helix (approximately 20% more buried surface area) .

Most KIR2DL3 variants display the binding pattern described above, but the KIR2DL3*005 allotype is notable for exhibiting HLA-C binding properties more similar to KIR2DL2 .

How does peptide selectivity influence KIR2DL3 recognition of HLA-C molecules?

KIR2DL3 exhibits significant peptide selectivity in its recognition of HLA-C molecules. Both KIR2DL2/L3 receptors demonstrate greater peptide selectivity than KIR2DL1, particularly when recognizing the lower-affinity HLA-C C2 allotypes . This selectivity allows NK cells to sense not only the downregulation of HLA class I molecules but also alterations in the HLA-presented peptidome that may occur during viral infections or malignant transformations .

Surface plasmon resonance (SPR) analysis of KIR2DL2 and KIR2DL3 binding to HLA-C*07:02 presenting various peptide substitutions shows that both receptors are particularly sensitive to changes at positions P7 and P8 of the bound peptide. For example:

Despite their structural differences, KIR2DL2 and KIR2DL3 share similar binding preferences across peptides with substitutions at P7 and P8 positions , suggesting that peptide discrimination patterns are largely conserved between these receptors.

What experimental approaches are optimal for studying KIR2DL3-HLA interactions?

Several complementary techniques have proven valuable for investigating KIR2DL3-HLA interactions:

• Crystallography: X-ray crystallography has been crucial for resolving the atomic structure of KIR2DL3 in complex with HLA-C molecules, revealing the precise contacts and binding geometry . This approach requires high-purity recombinant proteins and crystallization conditions that yield diffraction-quality crystals.

• Surface Plasmon Resonance (SPR): SPR provides quantitative binding affinity data and has been successfully used to compare KIR2DL3 and KIR2DL2 interactions with various HLA-C molecules presenting different peptides . This technique requires immobilizing one protein (typically the HLA molecule) on a sensor chip and measuring the binding kinetics of the KIR protein in solution.

• KIR-Fc Fusion Proteins: KIR-Fc fusion proteins (such as recombinant KIR2DL3-Fc chimeras) have been widely employed to assess the specificity of KIR2DL3 binding to different HLA-C allotypes . These constructs typically contain the extracellular domains of KIR2DL3 fused to the Fc portion of human IgG1.

• Cell-Based Binding Assays: Flow cytometry using recombinant KIR2DL3 to stain cells expressing different HLA-C molecules can assess binding in a more physiological context. Verification standards indicate that properly folded recombinant KIR2DL3 should bind to >20% of HEK293T cells expressing appropriate HLA-C molecules .

• Mutagenesis: Site-directed mutagenesis of specific residues in KIR2DL3 or HLA-C molecules has been instrumental in defining critical interaction points and understanding the functional consequences of polymorphisms .

What quality control parameters should be assessed when working with recombinant KIR2DL3?

When using recombinant KIR2DL3 for research, several quality control parameters should be evaluated:

• Purity: SDS-PAGE and size exclusion chromatography should confirm >95% purity of the recombinant protein.

• Folding and Activity: Functional binding assays should verify that the recombinant KIR2DL3 properly recognizes HLA-C molecules. For example, KIR2DL3-Fc chimera proteins should bind to >20% of HEK293T cells expressing appropriate HLA-C1 molecules .

• Endotoxin Levels: For cellular assays, endotoxin levels should be measured and kept below 0.1 ng/μg protein to avoid non-specific immune activation.

• Glycosylation Status: Native KIR2DL3 is glycosylated, and differences in glycosylation between recombinant and native forms may affect binding properties. Analysis by mass spectrometry can assess glycosylation patterns.

• Stability: Thermal shift assays can evaluate protein stability under different buffer conditions to optimize storage and experimental procedures.

How does KIR2DL3 contribute to NK cell education and function?

KIR2DL3 plays a crucial role in NK cell education (licensing) and functional regulation through its interaction with HLA-C1 molecules. When NK cells expressing KIR2DL3 encounter healthy cells displaying self HLA-C1 molecules, the inhibitory signals delivered through the ITIMs in KIR2DL3's cytoplasmic tail prevent NK cell activation. This inhibition is critical for self-tolerance.

During NK cell education, interactions between KIR2DL3 and self HLA-C1 molecules calibrate NK cell responsiveness. NK cells expressing KIR2DL3 that recognize self HLA-C1 become functionally competent ("licensed"), whereas those lacking this interaction remain hyporesponsive. This education process ensures that NK cells can effectively discriminate between healthy self cells and abnormal cells that have downregulated HLA expression.

The inhibitory function of KIR2DL3 is executed through its two ITIM domains within the long cytoplasmic tail, which block activating receptor clustering upon ligand binding . This mechanistic feature is shared with other inhibitory KIRs but with distinct binding avidities and specificities that contribute to the diverse NK cell repertoire.

What is the significance of KIR2DL3 polymorphisms in disease associations?

KIR2DL3 polymorphisms have been associated with various disease outcomes, particularly in infectious diseases and autoimmune conditions:

• Viral Infections: In hepatitis C virus (HCV) infection, the presence of KIR2DL3 (but not KIR2DL2) in combination with HLA-C1 alleles has been associated with increased likelihood of viral clearance . This suggests that the lower inhibitory capacity of KIR2DL3 compared to KIR2DL2 may permit more effective NK cell responses against infected cells.

• Autoimmune Diseases: In rheumatoid arthritis, patients who are positive for KIR2DL3 and negative for KIR2DS3 have been associated with earlier disease diagnosis . Similarly, KIR2DL3 (but not KIR2DL2) has been linked to the progression of ulcerative colitis in the presence of HLA-C1 alleles .

• Cancer: The configurations of inhibitory and activating KIRs, including KIR2DL3, can alter an individual's susceptibility to leukemia and influence outcomes in cancer immunotherapy .

These disease associations likely reflect the functional differences between KIR2DL3 and KIR2DL2, including their distinct binding geometries and avidities for HLA-C molecules. Additionally, KIR2DL2 is in linkage disequilibrium with the activating receptor KIR2DS2, while KIR2DL3 is not , which may contribute to differential disease outcomes.

How do structural differences between KIR2DL2 and KIR2DL3 influence functional outcomes in NK cells?

The subtle structural differences between KIR2DL2 and KIR2DL3 translate to significant functional consequences in NK cell biology. The different binding geometries observed in crystal structures, with KIR2DL3's D1 domain positioned ~3Å more toward the C-terminus of the peptide-binding groove compared to KIR2DL2 , result in:

• Avidity Differences: KIR2DL2 exhibits higher avidity for HLA-C1 allotypes than KIR2DL3, likely due to its more extensive contacts with the HLA α1-helix (~20% more buried surface area) .

• Cross-reactivity Patterns: KIR2DL2 shows broader cross-reactivity with HLA-C2 allotypes than KIR2DL3, expanding the range of ligands that can inhibit KIR2DL2-expressing NK cells .

• Peptide Sensitivity: While both receptors demonstrate similar peptide selectivity patterns, their structural differences may influence sensitivity to certain peptide-HLA combinations in physiological settings .

• Signaling Potency: The differences in binding geometry may affect the clustering of receptors and their associated signaling molecules, potentially influencing the strength and duration of inhibitory signals.

These structural and functional differences likely contribute to the distinct clinical associations observed between KIR2DL2 and KIR2DL3 in various diseases, including viral infections and autoimmune conditions .

What are the challenges and opportunities in developing recombinant KIR2DL3 for immunotherapy applications?

The development of recombinant KIR2DL3 for immunotherapeutic applications presents several challenges and opportunities:

Challenges:

• Allotypic Diversity: The polymorphic nature of both KIR2DL3 and its HLA-C ligands creates complexity in predicting interactions and outcomes across diverse patient populations.

• Peptide Sensitivity: KIR2DL3 binding is influenced by the peptides presented by HLA-C molecules, requiring careful consideration of the peptide repertoire in target tissues.

• Expression Systems: Ensuring proper folding, glycosylation, and functional activity of recombinant KIR2DL3 requires optimized expression systems that may differ from those used for research applications.

• Delivery and Pharmacokinetics: Developing effective methods for delivering recombinant KIR2DL3 to target tissues and understanding its in vivo pharmacokinetics represent significant challenges.

Opportunities:

• Modulating NK Cell Responses: Recombinant KIR2DL3 could potentially be used to modulate NK cell responses in settings where excessive NK activity contributes to pathology, such as certain autoimmune conditions.

• Blocking KIR-HLA Interactions: Engineered variants of KIR2DL3 could be developed to block inhibitory KIR-HLA interactions, potentially enhancing NK cell responses against tumors or virally infected cells.

• Diagnostic Applications: Recombinant KIR2DL3 could serve as a tool for assessing HLA-C expression patterns in patient samples, potentially guiding immunotherapy decisions.

• Research Tools: Well-characterized recombinant KIR2DL3 variants remain valuable tools for understanding fundamental aspects of NK cell biology and receptor-ligand interactions.

Recent advances in understanding the structural basis of KIR2DL3-HLA interactions provide a foundation for rational design approaches to modifying these interactions for therapeutic purposes .